Key result
In patients with metabolic syndrome, carrying the A-allele of the PLCL2 rs4618210 polymorphism was associated with a significantly lower risk of ischaemic stroke compared to GG homozygotes (OR 0.679).
Why the study?
PLCL2 was identified as a susceptibility locus for myocardial infarction, prompting investigation into whether its polymorphisms are associated with ischaemic stroke onset and prognosis in patients with metabolic syndrome.
Are PLCL2 gene polymorphisms associated with the risk of ischaemic stroke in patients with metabolic syndrome?
Case-Control (n=1,420)
Yes
Are PLCL2 gene polymorphisms associated with the risk of ischaemic stroke in patients with metabolic syndrome?
Genetic polymorphisms in the PLCL2 gene (rs4685423 and rs4618210) are associated with a decreased risk and later onset of ischaemic stroke in Chinese Han patients with metabolic syndrome.
May link PLCL2 variant to IS in MetS; hypothesis-generating and needs replication before any clinical use.
Background and aims A genome-wide association study (GWAS) reported PLCL2 on chromosome 3p24.3 (rs4618210:A>G) as a novel susceptibility locus for myocardial infarction in the Japanese population. As the most common pathological process, atherosclerosis leads to metabolic syndrome (MetS)-related ischaemic stroke (IS) and myocardial infarction. Hypothesizing that polymorphisms of the PLCL2 gene might be associated with the onset and prognosis of IS in MetS patients, we performed the following study in a Chinese Han population. Methods A total of 709 cases (patients with MetS plus IS) and 711 controls (patients with MetS) were enrolled. A fine-mapping strategy was adopted to identify tagged single nucleotide polymorphisms (SNPs) of the PLCL2 gene, and improved multiplex ligation detection reaction (iMLDR) technology was used to genotype the selected SNPs. Logistic regression was used to analyse the values of the selected SNPs for the risk of IS between the cases and controls, adjusting for sex, age, hypertension, dyslipidaemia, hyperglycaemia, smoking and drinking. To compare the mean age of IS onset among different risk score groups, a genetic risk score was constructed for each case. The cumulative risk of IS events in the case group was presented using a cumulative incidence curve. All cases were followed up for 3 months, and functional outcomes were recorded prospectively. Results Two SNPs (rs4685423 and rs4618210) were significantly related to the risk of IS in MetS patients. For rs4685423, patients who were AA homozygotes were less likely to suffer from IS than C-allele carriers (OR 0.718; 95% CI 0.567–0.909; multivariate-adjusted, P = 0.006). For rs4618210, A-allele carriers were less likely to develop IS than patients who were GG homozygotes (OR 0.679; 95% CI 0.548–0.841; multivariate-adjusted, P < 0.001). As the genetic risk score increased, the mean age at IS onset decreased (log-rank P = 0.010). There was no statistically significant difference in the distribution of the 90-day modified Rankin Scale (mRS) outcomes across the rs4685423 ( P = 0.319) or rs4618210 polymorphisms ( P = 0.148). Conclusions Our findings suggested that genetic polymorphisms of PLCL2 might be associated with the onset of MetS-related IS. Further studies are warranted to validate our findings in other ethnic populations.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a case-control in Ischaemic stroke in metabolic syndrome (n=1,420). PLCL2 gene polymorphisms (rs4618210 and rs4685423) vs. Reference genotypes (e.g., GG homozygotes for rs4618210) was evaluated on Risk of ischaemic stroke (OR 0.679, 95% CI 0.548-0.841, p=<0.001). In patients with metabolic syndrome, carrying the A-allele of the PLCL2 rs4618210 polymorphism was associated with a significantly lower risk of ischaemic stroke compared to GG homozygotes (OR 0.679).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: